December 2017 was a defining moment in our biosimilars journey when Biocon and partner Mylan became the first companies globally to receive U.S. Food and Drug Administration (FDA) approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) was the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S., and it made us the first Indian…
Category: Innovation
Biocon Presented PK-PD Data on Insulin Tregopil at American Diabetes Association, 78th Scientific Sessions – Suggesting an Oral Rapid Acting Insulin Option for Type 2 Diabetes Patients
Biocon recently presented data from its Insulin Tregopil clinical program at the American Diabetes Association’s (ADA) 78th Scientific Sessions held at Orlando, Florida, from 22nd to 26th June, 2018.
Biocon’s Landmark Achievement of First USFDA approval for Biosimilar Trastuzumab applauded by all including the Media
First Biosimilar Trastuzumab approved in the US
‘KRABEVA®’s Unique ‘Qual-Check’ Mechanism Ensures Patients Get a Quality-Ascertained Product’: Suresh Subramanian
Mr. Suresh Subramanian, Senior Vice President & Head Branded Formulations, Biocon shares his views on how KRABEVA® can make a significant impact in the biosimilars space.
Antimicrobial Resistance (AMR) – A global threat is here to stay!
Antimicrobial resistance (AMR) represents a global catastrophe that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.
Personalized Medicine – Myth or Reality?
By Sreesha Srinivasa, PhD
Associate Vice President, Research and Development, Biocon Research Limited.
Antibodies as Drugs
By Narendra Chirmule, PhD
Senior VP & Head of Research and Development,
Biocon Research Limited.
Can India Create the Next Apple or Google?
By Kiran Mazumdar Shaw
Chairman & Managing Director,
Biocon Limited.
Anemia – Sickle Cell Disease
By Narendra Chirmule, PhD
Senior Vice President & Head,
Research and Development,
Biocon Research Limited.
